GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kukje Pharma Co 002720.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

3,225

+0.78%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩175.50bn

FY2016FY2025

Net income

₩5.70bn

FY2016FY2025

Free cash flow

₩1.97bn

FY2016FY2025

Shareholders' equity

₩97.69bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩175.50bn₩156.46bn₩135.37bn₩126.58bn₩119.75bn₩130.39bn₩111.12bn₩107.68bn₩123.31bn₩120.68bn
Gross profit₩93.64bn₩82.50bn₩67.22bn₩63.25bn₩54.47bn₩64.80bn₩52.99bn₩48.81bn₩51.47bn₩53.78bn
Research and development₩3.66bn₩1.81bn₩2.65bn₩1.97bn₩2.77bn₩3.04bn₩2.60bn₩3.59bn₩3.29bn₩1.33bn
Operating income₩6.87bn₩6.70bn−₩5.63bn₩5.27bn−₩1.68bn₩6.04bn₩5.57bn₩3.29bn₩2.56bn₩3.97bn
Net income₩5.70bn₩5.21bn−₩8.42bn₩3.56bn−₩1.56bn₩2.20bn−₩4.76bn₩2.19bn₩1.09bn₩773.1m
Diluted earnings per share325.37297.24-480.55203.14-89.04125.80-271.87125.1962.3546.17

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩182.28bn₩165.55bn₩163.26bn₩136.59bn₩139.78bn₩145.63bn₩134.59bn₩126.23bn₩131.65bn₩129.46bn
Total liabilities₩84.57bn₩76.00bn₩78.31bn₩62.51bn₩71.20bn₩75.13bn₩73.64bn₩57.54bn₩63.87bn₩61.94bn
Debt—₩27.00bn———₩2.00bn₩35.06bn₩29.00bn₩34.50bn₩33.09bn
Shareholders' equity₩97.69bn₩89.54bn₩84.94bn₩74.07bn₩68.57bn₩70.48bn₩60.93bn₩68.67bn₩67.74bn₩67.50bn
Shares outstanding18m18m18m18m18m18m18m18m18m17m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩5.84bn₩3.94bn₩3.58bn₩6.50bn₩9.60bn₩5.10bn₩3.60bn₩13.25bn₩786.1m₩16.10bn
Capital spending−₩3.87bn−₩2.99bn−₩1.05bn−₩1.26bn−₩1.89bn−₩11.60bn−₩5.89bn−₩3.03bn−₩2.61bn−₩2.69bn
Free cash flow₩1.97bn₩945.2m₩2.53bn₩5.24bn₩7.70bn−₩6.50bn−₩2.28bn₩10.22bn−₩1.82bn₩13.41bn
Dividends paid−₩610.9m—————−₩515.1m−₩165.1m−₩157.9m−₩157.9m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩48.32bn₩43.98bn₩43.34bn₩45.63bn₩45.02bn₩41.50bn₩41.64bn₩39.65bn
Gross profit₩26.90bn₩23.81bn₩21.60bn₩24.94bn₩24.73bn₩22.38bn₩21.77bn₩21.10bn
Operating income₩2.29bn₩2.73bn−₩1.48bn₩2.50bn₩3.51bn₩2.30bn₩1.09bn₩1.68bn
Net income₩1.67bn₩2.15bn−₩731.5m₩1.91bn₩2.66bn₩1.85bn₩707.7m₩1.15bn
Diluted earnings per share95.38122.69-41.77109.30151.98105.8640.4265.73
Cash from operations₩7.21bn−₩1.17bn−₩4.34bn₩4.99bn₩3.45bn₩1.74bn₩771.0m₩2.71bn
Capital spending−₩668.0m−₩737.0m−₩2.78bn−₩474.0m−₩149.0m−₩459.0m−₩523.0m−₩1.04bn
Free cash flow₩6.54bn−₩1.91bn−₩7.13bn₩4.52bn₩3.30bn₩1.28bn₩248.0m₩1.67bn
Total assets₩185.21bn₩178.93bn₩182.28bn₩180.12bn₩171.73bn₩164.31bn₩165.55bn₩162.42bn
Debt————₩27.00bn₩27.00bn₩27.00bn₩27.00bn
Shareholders' equity₩99.36bn₩98.49bn₩97.69bn₩95.30bn₩93.39bn₩90.76bn₩89.54bn₩89.86bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue11.5%6.1%4.1%
Operating income9.2%2.6%12.6%
Net income17.0%20.9%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin53.1%51.6%50.5%48.1%
Operating margin4.1%2.2%2.1%2.5%
Net margin3.3%1.0%0.8%0.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings13.217.0-12.327.1-65.772.8-15.430.975.285.3
Price to sales0.40.60.80.80.91.20.70.60.70.6

Dividends and splits

Per share, in the currency the company pays

Paid for 1 years. Last went ex-dividend on 12 Mar 2026.

FY2026FY2025FY2019FY2018FY2017FY2015FY2014FY2012
Paid in the year30.0030.0025.9158.4697.7557.3867.38614.342
  • 21-for-20 split · 18 Mar 2022
  • 21-for-20 split · 2 Mar 2021
  • 1.02-for-1 split · 27 Dec 2018
  • 1.04-for-1 split · 27 Dec 2017
  • 21-for-20 split · 28 Dec 2016
  • 21-for-20 split · 29 Dec 2014

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.